Midomafetamine

Generic Name: Midomafetamine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅NO_₂

CAS Number: 42542-10-9

Unique Ingredient Identifier: KE1SEN21RM

Background: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication: Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

MDMA Plus Exposure Therapy for PTSD

Phase 2

Recruiting

Conditions: PTSD

Interventions: Drug: MDMA

First Posted Date: 2023-02-27

Last Posted Date: 2024-05-16

Lead Sponsor: Emory University

Target Recruit Count: 40

Registration Number: NCT05746572

Locations: 🇺🇸
Emory Brain Health Center, Atlanta, Georgia, United States

Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.

Phase 2

Not yet recruiting

Conditions: Post Traumatic Stress Disorder
MDMA ('Ecstasy')
Moral Injury

First Posted Date: 2023-02-16

Last Posted Date: 2023-02-16

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 60

Registration Number: NCT05732155

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

Phase 2

Recruiting

Conditions: Post-traumatic Stress Disorder
PTSD
Alcohol Use Disorder
Alcohol Dependence
Comorbidities and Coexisting Conditions

Interventions: Behavioral: Prolonged exposure therapy
Drug: Niacin
Drug: MDMA

First Posted Date: 2023-02-02

Last Posted Date: 2023-11-07

Lead Sponsor: University of Sydney

Target Recruit Count: 120

Registration Number: NCT05709353

Locations: 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Phase 2

Recruiting

Conditions: Cancer
Adjustment Disorders

Interventions: Drug: MDMA

First Posted Date: 2022-10-18

Last Posted Date: 2022-10-18

Lead Sponsor: Sunstone Medical

Target Recruit Count: 20

Registration Number: NCT05584826

Locations: 🇺🇸
Sunstone Medical, PC, Rockville, Maryland, United States

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: 4-bromo-2,5-dimethoxyphenethylamine (10 mg)
Drug: 4-bromo-2,5-dimethoxyphenethylamine (20 mg)
Other: Placebo
Drug: 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
Drug: 3,4-methylenedioxymethamphetamine
Drug: Psilocybin

First Posted Date: 2022-08-31

Last Posted Date: 2024-08-14

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT05523401

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Abuse Potential and Human Pharmacology of Methylone

Phase 1

Conditions: Substance Use
Healthy Subjects

Interventions: Drug: Methylone
Drug: Placebo
Drug: 3,4-methylenedioxymethamphetamine

First Posted Date: 2022-08-04

Last Posted Date: 2022-08-08

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 17

Registration Number: NCT05488171

Locations: 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers

Phase 2

Not yet recruiting

Conditions: Post-Traumatic Stress Disorder
Adjustment Disorders

Interventions: Drug: MDMA

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: Willa Hall

Target Recruit Count: 30

Registration Number: NCT05455996

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

Early Phase 1

Completed

Conditions: Social Behavior
Motivation
Stimulant Use
MDMA ('Ecstasy')

Interventions: Drug: MDMA
Drug: Methamphetamine
Drug: placebo oral tablet

First Posted Date: 2022-05-18

Last Posted Date: 2024-01-24

Lead Sponsor: University of Chicago

Target Recruit Count: 43

Registration Number: NCT05379959

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Acute Effects of R- and S-MDMA in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: R-3,4-methylenedioxymethamphetamine (250 mg)
Drug: 3,4-methylenedioxymethamphetamine
Drug: S-3,4-methylenedioxymethamphetamine
Drug: R-3,4-methylenedioxymethamphetamine (125 mg)
Other: Placebo

First Posted Date: 2022-03-14

Last Posted Date: 2024-01-17

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT05277636

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans

Phase 2

Withdrawn

Conditions: PTSD

Interventions: Drug: Midomafetamine
Behavioral: Therapy

First Posted Date: 2021-12-30

Last Posted Date: 2024-10-30

Lead Sponsor: Lykos Therapeutics

Registration Number: NCT05173831

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy